What is AiCure?
Founded in 2009 and headquartered in New York, AiCure operates at the intersection of advanced data analytics and medical research. The company provides a sophisticated platform designed to facilitate continuous monitoring and intervention, which significantly enhances statistical power and reduces sample size requirements in clinical trials. By leveraging an extensive intellectual property portfolio, AiCure addresses critical inefficiencies in drug development and patient adherence. Its market position is bolstered by a history of support from both the National Institutes of Health and a diverse syndicate of institutional backers, positioning the firm as a key player in the digital health transformation.
How much funding has AiCure raised?
AiCure has raised a total of $68.8M across 5 funding rounds:
Series A
$12.3M
Series B
$15M
Series C
$24.5M
Debt
$1M
Other Financing Round
$16M
Series A (2016): $12.3M with participation from New Leaf Venture Partners, Pritzker Group, and Tribeca Venture Partners
Series B (2017): $15M led by Silicon Valley Bank and Baird Capital
Series C (2019): $24.5M supported by Silicon Valley Bank, Tribeca Venture Partners, SpringRockVentures, BairdCapital, Accelmed Growth Partners, New Leaf Venture Partners, Pritzker Group, Asahi Kasei Corporation, Biomatics Capital, Palisades Growth Capital, and Singtel Innov8
Debt (2020): $1M featuring PPP
Other Financing Round (2024): $16M, investors not publicly disclosed
Key Investors in AiCure
Silicon Valley Bank
SVB Financial Group offers commercial and private banking, asset management, and specialized investment services, acting as a cornerstone financial partner for high-growth technology firms.
Tribeca Venture Partners
A New York-based multi-stage venture capital firm that partners with determined founders to leverage emerging technologies and drive significant market disruption.
New Leaf Venture Partners
A global venture capital firm dedicated to corporate technology spinouts, providing a systematic process for commercializing innovations from R&D labs.
What's next for AiCure?
The recent capital injection serves as a catalyst for AiCure to scale its enterprise-level operations and further refine its AI-driven intervention models. As the healthcare industry increasingly shifts toward value-based care and data-centric clinical research, AiCure is well-positioned to expand its footprint. Future strategic initiatives will likely focus on deepening its integration within global pharmaceutical pipelines and enhancing its population health analytics capabilities. By maintaining its focus on high-impact, technology-enabled health outcomes, the company is poised to sustain its growth trajectory and continue attracting high-caliber institutional interest.
See full AiCure company page
